ReAlta Life Sciences key facts
as of Oct 2026- Developer of immunomodulatory therapeutics designed for the treatment of acute inflammatory and rare diseases.
- ReAlta Life Sciences is valued at approximately $230.0M as of Oct 2026, set at its later-stage round, Apr 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $155.4M across 5 recorded rounds; the latest was Early Stage VC ($25.0M) in Dec 2024.
- Notable investors include Virginia Innovation Partnership Corporation, Children's Research Holdings, Cock Island Capital, Cystic Fibrosis Foundation, Eriko Life Science Ventures — 12 tracked in total.
- ReAlta Life Sciences has filed 7 Form Ds with the SEC since 2018, most recently May 2025 ($12.0M sold to 85 investors).
- Status: Privately Held (backing).
Valued at $230.0M at its later-stage round, Apr 2026. Nothing has traded since.
- ·The complete investor list: 12 names
- ·Watch ReAlta Life Sciences: the Monday email on marks, rounds and moves
ReAlta Life Sciences funding rounds
5 roundsWho backs ReAlta Life Sciences
12+Membership and data by Private Market View
ReAlta Life Sciences valuation
ReAlta Life Sciences was valued at $230 million at its later-stage round in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has ReAlta Life Sciences raised?
ReAlta Life Sciences has raised $155 million across 5 recorded rounds since 2018. The largest was a $4.8 million seed round in Sep 2018; the most recent was a $25 million early-stage round in Dec 2024.
ReAlta Life Sciences has filed 7 Form Ds with the SEC since 2018, most recently in May 2025 ($12 million sold to 85 investors).
ReAlta Life Sciences investors
12 investors are on record for ReAlta Life Sciences, including Virginia Innovation Partnership Corporation, Children's Research Holdings, Cock Island Capital and Cystic Fibrosis Foundation. The early-stage round in Dec 2024 drew 109 investors.
About ReAlta Life Sciences
Developer of immunomodulatory therapeutics designed for the treatment of acute inflammatory and rare diseases. The company utilizes engineered peptides derived from a viral capsid protein to simultaneously inhibit early complement pathway activation and neutrophil-mediated inflammation, enabling healthcare professionals to address medical needs through beneficial inhibition of the complement system and inflammatory mechanisms.
- Sector
- Healthcare
- HQ
- Norfolk, VA, United States
- Employees
- 25
- Website
- realtalifesciences.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.